{"id":"W4414842977","doi":"10.3389/fonc.2025.1645509","title":"Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma","year":2025,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; Princess Margaret Cancer Centre","funders":"Astellas Pharma; Novo Nordisk; Eisai; Ipsen; BeiGene; Regeneron Pharmaceuticals; Gilead Sciences; Merck KGaA; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Quality of life (healthcare); Head and neck squamous-cell carcinoma; Chemoradiotherapy; Head and neck; Head and neck cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003305467,0.0005547529,0.0009889732,0.0001848496,0.0003823719,0.000521989,0.0005191081,0.000953099,0.004756649],"category_scores_gemma":[0.00243541,0.0002604967,0.001378498,0.0003693625,0.0004214329,0.0005889893,0.0006105155,0.001235442,0.0004197758],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000512657,"about_ca_system_score_gemma":0.001171318,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007363478,"about_ca_topic_score_gemma":0.001321127,"domain_scores_codex":[0.9988329,0.0005858837,0.0001142095,0.0001984259,0.0001480826,0.0001204549],"domain_scores_gemma":[0.9988972,0.0002357743,0.000476297,0.00008849399,0.0001125295,0.0001896723],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.91985,0.009439504,0.02272632,0.00187573,0.00243366,0.00005561195,0.0003249394,0.0005202371,0.01083334,0.0001060823,0.001151442,0.03068313],"study_design_scores_gemma":[0.3387514,0.3841826,0.2582614,0.0003107192,0.005230808,0.0002388604,0.0003228778,0.001028294,0.006385678,0.000383019,0.004825649,0.00007880493],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959002,0.0009047672,0.0001595519,0.0001013822,0.00003330488,0.0009696821,0.001204984,0.0000121962,0.0007138565],"genre_scores_gemma":[0.9954512,0.0002463539,0.0003464141,0.0001615092,0.00003014429,0.002473496,0.0008424042,0.000003369099,0.0004452885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004756649,"threshold_uncertainty_score":0.01748121,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04572749986883212,"score_gpt":0.3610465639488075,"score_spread":0.3153190640799753,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}